IMAB

I-MAB

1.76 USD
+0.01 (+0.57%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

I-MAB stock is down -2.22% since 30 days ago. The next earnings date is May 31, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 4 May’s closed higher than April.

About I-MAB

I-Mab discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. The company is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases. Its product candidates also includes Enoblituzumab, which has completed Phase 2 clinical trials for head and neck cancer, and other oncology diseases.